Patients with relapsed diffuse large B cell lymphoma (DLBCL) have limited curative options, once their tumor fails to respond to standard chemotherapy regimens. Our group and others have recently demonstrated that activating the patients’ own immune cells can induce clinical responses, even in chemotherapy-refractory DLBCL patients. The central goal of this SCOR is to establish a collaborative team-science approach aiming at the development of new immune therapeutic strategies for DLBCL. Our ultimate goal is to translate our findings into novel clinical trials to improve the cure rate of patients with DLBCL.
New York, NY